AIM ImmunoTech Completes Pancreatic Cancer Trial Enrollment
AIM ImmunoTech reported Q2 financial results and completed dosing in its phase 2 pancreatic cancer trial, positioning the company for potential phase 3 development and key clinical data in late 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day